These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21253816)

  • 21. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
    Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Back pain and acne conglobata: SAPHO syndrome].
    Kühn F; Fehr S; Stoll T
    Praxis (Bern 1994); 2007 Apr; 96(15):591-5. PubMed ID: 17506389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
    Braun J; van der Horst-Bruinsma IE; Huang F; Burgos-Vargas R; Vlahos B; Koenig AS; Freundlich B
    Arthritis Rheum; 2011 Jun; 63(6):1543-51. PubMed ID: 21630245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome.
    Wagner AD; Andresen J; Jendro MC; Hülsemann JL; Zeidler H
    Arthritis Rheum; 2002 Jul; 46(7):1965-8. PubMed ID: 12124882
    [No Abstract]   [Full Text] [Related]  

  • 27. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
    Haraoui B; Krelenbaum M
    Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
    Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
    Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept.
    Vilar-Alejo J; Dehesa L; de la Rosa-del Rey P; Novoa-Medina J; Valerón Almazán P; Santana Medina N; Bastida J
    Acta Derm Venereol; 2010 Sep; 90(5):531-2. PubMed ID: 20814638
    [No Abstract]   [Full Text] [Related]  

  • 30. Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.
    Aksu K; Donmez A; Ertan Y; Keser G; Inal V; Oder G; Tombuloglu M; Kabasakal Y; Doganavsargil E
    Rheumatol Int; 2007 Dec; 28(2):185-7. PubMed ID: 17622534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of genetic predisposition of de novo uveitis with etanercept in ankylosing spondylitis.
    Killian M; Touraine R; Amouzougan A; Thomas T; Marotte H
    Ann Rheum Dis; 2015 Mar; 74(3):e22. PubMed ID: 25467296
    [No Abstract]   [Full Text] [Related]  

  • 32. New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome.
    Magrey M; Khan MA
    Curr Rheumatol Rep; 2009 Oct; 11(5):329-33. PubMed ID: 19772827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of sarcoidosis following etanercept treatment: a report of three cases.
    Skoie IM; Wildhagen K; Omdal R
    Rheumatol Int; 2012 Apr; 32(4):1049-53. PubMed ID: 20062997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of etanercept in the treatment of acne conglobata].
    Vega J; Sánchez-Velicia L; Pozo T
    Actas Dermosifiliogr; 2010 Jul; 101(6):553-4. PubMed ID: 20738977
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of sarcoidosis during etanercept therapy.
    González-López MA; Blanco R; González-Vela MC; Fernández-Llaca H; Rodríguez-Valverde V
    Arthritis Rheum; 2006 Oct; 55(5):817-20. PubMed ID: 17013853
    [No Abstract]   [Full Text] [Related]  

  • 37. New-onset psoriasis associated with etanercept therapy.
    Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
    J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
    [No Abstract]   [Full Text] [Related]  

  • 38. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
    Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics of pediatric synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome: the first Chinese case series from a single center.
    Wu N; Shao Y; Huo J; Zhang Y; Cao Y; Jing H; Zhang F; Yu C; Yu Y; Li C; Song H; Zhang W
    Clin Rheumatol; 2021 Apr; 40(4):1487-1495. PubMed ID: 32929648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of etanercept on iritis in patients with ankylosing spondylitis.
    Rosenbaum JT
    Arthritis Rheum; 2004 Nov; 50(11):3736-7. PubMed ID: 15529379
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.